EPO906 epothilone B
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoid
Conditions
Carcinoid, Neuroendocrine Tumors
Trial Timeline
Jul 1, 2002 → Apr 1, 2007
NCT ID
NCT00050349About EPO906 epothilone B
EPO906 epothilone B is a phase 2 stage product being developed by Novartis for Carcinoid. The current trial status is completed. This product is registered under clinical trial identifier NCT00050349. Target conditions include Carcinoid, Neuroendocrine Tumors.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00050349 | Phase 2 | Completed |
Competing Products
20 competing products in Carcinoid